Genetic Polymorphisms and Cisplatin- Related Nephrotoxicity
Journal: Global Journal of Cancer Therapy (Vol.1, No. 1)Publication Date: 2015-11-06
Authors : Arundhati Bag Lalit Mohan Jeena; Niladri Bag;
Page : 001-004
Keywords : Cisplatin; DNA repair enzymes; Metabolic enzymes; Nephrotoxicity; OCT; Polymorphisms;
Abstract
Cis- diamminedichloroplatinum (cisplatin) is one of the most commonly used present day hemotherapeutic agents. It is used to treat a wide range of cancers including head and neck, lung, gastrointestinal tract, ovarian and genitourinary cancers. However, dose- limiting toxicity is often associated with cisplatin. It is known that cisplatin works more effectively with dose escalation, but significant risk for nephrotoxicity is often associated with higher doses [1].
Other Latest Articles
- Whatsapp as a Means of Sharing Information among LIS Professionals of North-East India: A Study
- Role of Social Networking Sites to Modernize Public Libraries
- Exploring the Role of Educational Aspiration to Enhance the Mathematics Achievement of Secondary School Students
- The Effectiveness of Hand Massage, Foot Massage and Combination on Pain Intensity of Post Sectio Caesarea
- Development of Learning in Human Brain
Last modified: 2018-10-05 20:51:37